Symptom mate

Symptom checkers provide individuals with a fast way to identify possible causes for their medical symptoms. Users enter their symptoms and respond to targeted follow-up questions that help narrow the possible causes. Studies published in the British Medical Journal (2020), MJA (2020), and PLOS ONE (2021) evaluated online symptom checkers for condition coverage, diagnostic accuracy, and appropriateness of urgent care advice. We used these studies to assemble this list of the best free symptom checkers on the web.Diagnostic accuracy represents the percentage of result sets that yielded a correct diagnosis among the top three results (averaged across studies). Incredibly well designed and accurate symptom checker. Diagnostic accuracy of 77%. ada.com - Registration Required, App Only Buoy is an AI-powered chat-based symptom checker. Diagnostic accuracy of 52%. buoyhealth.com Relied upon by doctors and nurses around the world. Diagnostic accuracy of 68%. symptomchecker.isabelhealthcare.com Powered by Infermedica. Expect many branched logic follow-up questions. Diagnostic accuracy of 60%. symptomate.com Most popular online symptom checker with interactive body map. Diagnostic accuracty of 59%. symptoms.webmd.com Additional Tools Easy to use symptom drill down tool powered by Harvard Medical School. drugs.com Limited but easy to use general symptom checker. familydoctor.org Self-care health app. Includes conversation-themed symptom checker. livehealthily.com Question-based symptom checker. Unfortunately, registration is required. khealth.com - Registration Required, App Only Choose your primary symptom and related factors to narrow potential medical conditions. mayoclinic.org AI-based medical assistant for triage and pre-diagnosis. Based in Spain. Mediktor High quality dermatology information site offering a rash and skin condition identifier tool. skinsight.com User-friendly symptom checker from Tokyo-based Ubie Health. ubiehealth.com

A few minutes each day will also help. More on Albino Oscar BreedingAs long as this fish thinks they’ve found a suitable mate, you can breed any combination of individuals from different varieties. Also, when the fish is ready to spawn they’ll flare their gill and use their fins to indicate to their mate. Usually, this can be a simple fin waggling or vibration.They usually lay their small white eggs on a rock or on a clean flattened horizontal or vertical surface. , Usually, the adhesive eggs are about a millimeter in diameter and opaque white, resembling dead eggs of other fish. Typically, they produce up to 3000 opaque white eggs.They reach sexual maturity around one year of age and continue to reproduce until 9 to 10 years. Therefore, it is one of the tedious fish to breed in captivity. Furthermore, detailed information regarding their reproduction in the wild is scarce.FAQsThere are some frequently asked questions related toAlbino Oscar, this section answers these questions:Are albino Oscars less aggressive?The albino oscar is considerably less aggressivethan most other medium and large cichilds. But, they do have a voraciousappetite and will eat any fish or invertebrate that will fit (or nearly fit) inits mouth. Furthermore, of all the oscars the albinos are the least aggressive.Why is my Oscar fish turning white?Your oscar fish turning white could be a symptom of Ich known as white spot disease which s a very common disease problem of all aquarium fish including oscars. It is caused by Ichthyophthirius multifillis, a protozoan parasite. Usually, this disease is most commonly brought into an aquarium by the addition of new fish, live plants or live food items.Do albino oscar change color?There are several factors that can change an oscar color. They include nutrition, water quality, stress level and tank mates. And a change in water quality or water parameters can cause a color change in an oscar. Also, an albino oscar can change color during feeding. They could also change color when they are spooked or agitated by tank mates. It could also be a sign of general unhappiness.Where do Albino Oscars live in the wild?Wild populations are found in China, NorthernAustralia, and Florida, the USA as a byproduct of the ornamental fish trade.Can different type of Oscars be kept together?Oscars can be kept together, and this is the safest option. Only ensure to follow the stocking guidelines. Majorly, you are to ensure they have enough space in other to reduce territory dispute. In addition, you are to move juveniles to a new tank with a sponge filter for the best chance of survival. Also, you are to feed them around 2-4 times a day to help them grow quickly. Furthermore, you will have to move them again as they get bigger. Mainly because the tank will get too small and their growth will be stunted.How many Oscar fish can be kept together?Despite Oscar’s aggressive behavior, they enjoy staying together or living as pairs. Therefore, you can keep 2 Oscars

Histologic resolution (defined as ≤6 eosinophils (eos) / high powered field (hpf) in the esophagus) and (2) symptomatic improvement as measured by absolute change in dysphagia symptom questionnaire (DSQ). Co-Primary Endpoints LirentelimabHigh Dose (n=91) LirentelimabLow Dose (n=93) Placebo (n=92) Histologic Endpoint: Proportion of responders (eos ≤6 /hpf) as determined by esophageal tissue eosinophil counts 1 87.9%(p 92.5% (p 10.9% Symptom Primary Endpoint: Absolute mean change in patient reported Dysphagia Symptom Questionnaire (DSQ)2 DSQ Baseline:34.2 DSQ Baseline:36.4 DSQ Baseline:35.2 -17.4(p=0.237) -11.9(p=0.247) -14.6 1 = A responder is a patient achieving the following peak eosinophil counts: ≤6 eosinophils (eos) / high powered field (hpf) in 1 hpf in the esophagus. Endpoint assessed at end of Week 24.2 = DSQ is a patient reported symptom questionnaire assessing difficulty swallowing. Endpoint assessed as absolute mean change from baseline to Weeks 23-24.The safety results of the trial were generally consistent with previously reported lirentelimab studies. No new safety signals were observed. Mild to moderate infusion-related reactions (including flushing, feeling of warmth, headache, nausea, and/or dizziness) occurred in 39% of high dose lirentelimab- treated patients, 26% of low dose lirentelimab-treated patients and 12% of placebo-treated patients.Phase 3 ENIGMA 2 Study DesignThe randomized, double-blind, placebo-controlled Phase 3 trial of intravenous lirentelimab enrolled 180 patients with EG and/or EoD. Patients were required to be moderately to severely symptomatic based on a patient reported symptom questionnaire and have biopsy-confirmed eosinophilia of the stomach (≥30 eosinophils/hpf in 5 hpfs) and/or duodenum (≥30 eosinophils/hpf in 3 hpfs). Patients were randomized 1:1 to receive: 1.0 mg/kg of lirentelimab for the first month followed by five doses of 3.0 mg/kg given monthly or (b) a monthly placebo. Disease symptoms were measured daily using a patient reported symptom questionnaire that scored 6 symptoms (abdominal pain, nausea, bloating, early satiety, abdominal cramping, loss of appetite) each on a scale from 0 to 10 (TSS). Co-primary endpoints were (1) proportion of responders with ≤4 eos/hpf in 5 hpfs in the stomach and/or ≤15 eos/hpf in 3 hpfs in the duodenum at the end of week 24 and (2) absolute change from baseline in TSS at weeks 23-24.Phase 2/3 KRYPTOS Study DesignThe randomized, double-blind, placebo-controlled Phase 2/3 trial of intravenous lirentelimab enrolled 276 patients with EoE. Patients were required to be moderately to severely symptomatic based on the dysphagia symptom questionnaire (DSQ) and have biopsy-confirmed eosinophilia of the esophagus (≥15 eosinophils in 1 hpf). Patients were randomized 1:1:1 to receive: 1.0 mg/kg of lirentelimab for the first month followed by five doses of 3.0 mg/kg given monthly (b) monthly 1.0 mg/kg of lirentelimab (c) a monthly placebo. Disease symptoms were measured daily using a patient reported symptom questionnaire that assessed difficulty swallowing. Co-primary endpoints were (1) proportion of responders with ≤6 eosinophils in 1 hpf in the esophagus and (2) absolute change in dysphagia symptom questionnaire from baseline.About AllakosAllakos is a clinical stage biotechnology company developing antibodies that target immunomodulatory receptors present on immune effector cells involved in allergic, inflammatory, and proliferative diseases. The Company’s lead antibody,